Takeda Prices Oral Multiple Myeloma Follow-On Ninlaro On Par With Velcade
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval of the next-generation proteasome inhibitor ixazomib will pave the way for an all-oral combination with Revlimid and dexamethasone and give Takeda an opportunity to extend its oncology franchise beyond Velcade, which could see generic competition in late 2017.